Based on KEYNOTE-811, would you add pembrolizumab for HER2+ distal esophageal adenocarcinoma with new supraclavicular lymph nodes if treated previously with concurrent chemoradiation and PD-L1 CPS of 3?  

There are a few important pieces of information needed to make a good therapeutic decision in this case: Age and comorbidities of the patient, performance status. Duration of progression free interval since finishing Chemo-Rads. What kind of imaging is done to assess extent of disease.  ...

There has been an explosion of new positive data in gastroesophageal cancer and keeping up with the data has been dizzying. The KEYNOTE-811 data established CAPEOX + trastuzumab + pembrolizumab (regardless of PD-L1 CPS status) as the standard of care for HER-2 positive disease. The data that the que...